Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the clinical activity of tasquinimod in advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas in patients who progressed after standard therapies Clinical activity will be measured by the proportion of patients who have neither progressed nor died at a prespecified timepoint (progression free survival [PFS] rate): • In advanced or metastatic hepatocellular carcinoma (HCC) after one line of sorafenib • In advanced or metastatic ovarian carcinoma (OC) resistant to platinum containing therapy • In metastatic renal cell carcinoma (mRCC) previously treated with vascular endothelial growth factor (VEGF) inhibitor • In advanced or metastatic gastric carcinoma (GC) after one line of platinum containing therapy.
Critère d'inclusion
- advanced or metastatic hepatocellular, ovarian, renal cell and gastric carcinomas in patients who have progressed after standard therapies